U.S. Physical Therapy (USPH)
(Delayed Data from NYSE)
$81.64 USD
-8.36 (-9.29%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $81.47 -0.17 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.64 USD
-8.36 (-9.29%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $81.47 -0.17 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
OPCH or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OPCH vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Surges 3.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
U.S. Physical Therapy (USPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 13.46% and 6.19%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Chemed (CHE) Q1 Earnings Lag Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -2.03% and 2.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Encompass Health (EHC) Soars 11.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Encompass Health (EHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Soars 3.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
U.S. Physical Therapy (USPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
U.S. Physical Therapy (USPH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 5.45% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.08% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Will ATI Physical Therapy, Inc. (ATIP) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita HealthCare (DVA) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.12% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Q3 Earnings Match Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 0% and 2.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -3.23% and 1.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Oak Street Health, Inc. (OSH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of -34.69% and 0.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.
DaVita HealthCare (DVA) Surges 6%: Is This an Indication of Further Gains?
by Zacks Equity Research
DaVita HealthCare (DVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Stocks to Watch From a Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.
U.S. Physical Therapy (USPH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 3.17% and 1.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: U.S. Physical Therapy (USPH) Q1 Earnings Expected to Decline
by Zacks Equity Research
U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed (CHE) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 6.68% and 1.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?